Gregory J. Kato

List of Publications by Year
in descending order

326	14,521	16411	22102
papers	citations	h-index	g-index

338	338	338	10674
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Gene Therapy as the New Frontier for Sickle Cell Disease. Current Medicinal Chemistry, 2022, 29, 453-466.	1.2	6
2	Plasma-Derived Hemopexin as a Candidate Therapeutic Agent for Acute Vaso-Occlusion in Sickle Cell Disease: Preclinical Evidence. Journal of Clinical Medicine, 2022, 11, 630.	1.0	15
3	Safety of liver biopsy in patients with sickle cell related liver disease: A singleâ€center experience. American Journal of Hematology, 2022, 97, .	2.0	1
4	Molecular mechanisms of hepatic dysfunction in sickle cell disease: lessons from Townes mouse model. American Journal of Physiology - Cell Physiology, 2022, 323, C494-C504.	2.1	2
5	Immunomodulatory actions of a kynurenine-derived endogenous electrophile. Science Advances, 2022, 8, .	4.7	4
6	Identifying adolescent and young adult patients with sickle cell disease at highest risk of death. American Journal of Hematology, 2021, 96, 9-11.	2.0	2
7	Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2021, 325, 1513.	3.8	24
8	Lactate dehydrogenase to carboxyhemoglobin ratio as a biomarker of heme release to heme processing is associated with higher tricuspid regurgitant jet velocity and early death in sickle cell disease. American Journal of Hematology, 2021, 96, E315-E318.	2.0	1
9	Exerciseâ€induced changes of vital signs in adults with sickle cell disease. American Journal of Hematology, 2021, 96, 1630-1638.	2.0	2
10	Targeted Proteomics of Pulmonary Hypertension in Sickle Cell Disease. Blood, 2021, 138, 981-981.	0.6	0
11	Platelet Extracellular Vesicles Drive Inflammasomeâ€“IL-1Î²â€“Dependent Lung Injury in Sickle Cell Disease. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 33-46.	2.5	66
12	Nrf2 deficiency in mice attenuates erythropoietic stress-related macrophage hypercellularity. Experimental Hematology, 2020, 84, 19-28.e4.	0.2	8
13	Kynurenine-derived Electrophiles: Potential Adaptive Mediators in Sickle Cell Disease. Free Radical Biology and Medicine, 2020, 159, S35-S36.	1.3	0
14	Serum albumin is independently associated with higher mortality in adult sickle cell patients: Results of three independent cohorts. PLoS ONE, 2020, 15, e0237543.	1.1	3
15	The CYB5R3 c . 350C >G and G6PD A alleles modify severity of anemia in malaria and sickle cell disease. American Journal of Hematology, 2020, 95, 1269-1279.	2.0	8
16	Heme Induces IL-6 and Cardiac Hypertrophy Genes Transcripts in Sickle Cell Mice. Frontiers in Immunology, 2020, 11, 1910.	2.2	17
17	147 A Prospective Phase II, Open-Label, Single-arm, Multicenter Study to Assess the Efficacy and Safety of SEG101 (Crizanlizumab) in Sickle Cell Disease Patients With Priapism (SPARTAN). Journal of Sexual Medicine, 2020, 17, S43.	0.3	0
18	Impaired Bile Secretion Promotes Hepatobiliary Injury in Sickle Cell Disease. Hepatology, 2020, 72, 2165-2181.	3.6	12

#	Article	IF	Citations
19	Sickle particulars of microparticles. Blood, 2020, 136, 154-155.	0.6	1
20	Tricuspid regurgitation velocity and other biomarkers of mortality in children, adolescents and young adults with sickle cell disease in the United States: The <scp>PUSH</scp> study. American Journal of Hematology, 2020, 95, 766-774.	2.0	19
21	The Worst Things in Life are Free: The Role of Free Heme in Sickle Cell Disease. Frontiers in Immunology, 2020, 11, 561917.	2.2	39
22	Exercise Induced Changes of Vital Signs in Adults with Sickle Cell Disease. Blood, 2020, 136, 59-60.	0.6	1
23	Microvascular Stasis Inhibition By Hemopexin in the Townes Mouse Model of Sickle Cell Disease. Blood, 2020, 136, 9-9.	0.6	0
24	Prevention of Heme-Induced Human Endothelial Cell Activation By Hemopexin in Vitro. Blood, 2020, 136, 8-8.	0.6	0
25	Title is missing!. , 2020, 15, e0237543.		0
26	Title is missing!. , 2020, 15, e0237543.		0
27	Title is missing!. , 2020, 15, e0237543.		0
28	Title is missing!. , 2020, 15, e0237543.		0
29	Title is missing!. , 2020, 15, e0237543.		0
30	Title is missing!. , 2020, 15, e0237543.		0
31	Sickle cell vasculopathy: vascular phenotype on fire!. Journal of Physiology, 2019, 597, 993-994.	1.3	4
32	Cardiac expression of HMOX1 and PGF in sickle cell mice and haemâ€treated wild type mice dominates organ expression profiles via Nrf2 (Nfe2l2). British Journal of Haematology, 2019, 187, 666-675.	1.2	6
33	Validation of a composite vascular highâ€risk profile for adult patients with sickle cell disease. American Journal of Hematology, 2019, 94, E312-E314.	2.0	3
34	Free heme regulates placenta growth factor through NRF2-antioxidant response signaling. Free Radical Biology and Medicine, 2019, 143, 300-308.	1.3	14
35	Identifying Clinical and Research Priorities in Sickle Cell Lung Disease. An Official American Thoracic Society Workshop Report. Annals of the American Thoracic Society, 2019, 16, e17-e32.	1.5	33
36	Sickle cells and sickle trait in thrombosis. Blood, 2019, 133, 2463-2463.	0.6	7

#	Article	IF	Citations
37	Health-related quality of life in sickle cell disease. Nature Reviews Disease Primers, 2019, 5, 27.	18.1	3
38	The Role of Platelets in Sickle Cell Disease. , 2019, , 563-580.		2
39	End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings. Blood Advances, 2019, 3, 4002-4020.	2.5	21
40	Sleep phenotype in the Townes mouse model of sickle cell disease. Sleep and Breathing, 2019, 23, 333-339.	0.9	11
41	Sickle related events following cardiac catheterisation: risk implication for other invasive procedures. British Journal of Haematology, 2019, 185, 778-780.	1.2	0
42	Anakinra, What Is Thy Bidding in Pulmonary Hypertension?. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 267-269.	2.5	2
43	A Phase II Trial of Topical Sodium Nitrite in Patients with Sickle Cell Disease and Leg Ulcers. Blood, 2019, 134, 2292-2292.	0.6	1
44	Impaired Bile Secretion Promotes Chronic Liver Injury in Sickle Cell Disease. Blood, 2019, 134, 3536-3536.	0.6	1
45	A Prospective Phase II, Open-Label, Single-Arm, Multicenter Study to Assess the Efficacy and Safety of SEG101 (Crizanlizumab) in Sickle Cell Disease Patients with Priapism (SPARTAN). Blood, 2019, 134, 1007-1007.	0.6	0
46	360o View of a Day Hospital Program Performing Exchange Transfusion and Outpatient Pain Management on Adults with Sickle Cell Disease. Blood, 2019, 134, 5873-5873.	0.6	0
47	Sickle Cell Disease Promotes Dysregulation of Hepatic Iron Homeostasis By Regulating Hepcidin Expression. Blood, 2019, 134, 958-958.	0.6	0
48	Lactate Dehydrogenase to Carboxyhemoglobin Ratio As a Biomarker of Heme Release to Heme Processing Is Associated with Higher Tricuspid Regurgitant Jet Velocity and Early Death in Sickle Cell Disease. Blood, 2019, 134, 2274-2274.	0.6	0
49	Macrophage Hypercellularity Accompanies Erythroid Hyperplasia in Sickle Cell Mice and during Recovery from Blood Loss in Wild Type Mice. Blood, 2019, 134, 3528-3528.	0.6	0
50	Nrf2 Null Mice Are Deficient in CD169+ Macrophages, Associated with Impaired Erythroid Response and Delayed Recovery from Acute Blood Loss. Blood, 2019, 134, 1038-1038.	0.6	0
51	Sickle cell disease. Nature Reviews Disease Primers, 2018, 4, 18010.	18.1	764
52	Haem augments and iron chelation decreases tollâ€like receptor 4 mediated inflammation in monocytes from sickle cell patients. British Journal of Haematology, 2018, 181, 552-554.	1.2	7
53	Brief topical sodium nitrite and its impact on the quality of life in patients with sickle leg ulcers. Medicine (United States), 2018, 97, e12614.	0.4	3
54	Exercise training: a prescription for sickle-cell disease?. Lancet Haematology,the, 2018, 5, e502-e503.	2.2	1

#	Article	IF	Citations
55	Clinical Outcomes Associated With Sickle Cell Trait. Annals of Internal Medicine, 2018, 169, 619.	2.0	78
56	Simultaneous polymerization and adhesion under hypoxia in sickle cell disease. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 9473-9478.	3.3	55
57	Abstract Animations for the Communication and Assessment of Pain in Adults: Cross-Sectional Feasibility Study. Journal of Medical Internet Research, 2018, 20, e10056.	2.1	16
58	Clinical and Laboratory Predictors of 30-Day Hospital Readmission Risk in Adult Patients with Sickle Cell Disease. Blood, 2018, 132, 2384-2384.	0.6	0
59	Assessment of Iron Overload Impact on QTc Interval in Patients with Sickle Cell Disease. Blood, 2018, 132, 3673-3673.	0.6	0
60	Heterogeneity in Multi-Organ Expression of HO-1 and PlGF in Sickle Mice Mimic Exposure of Non-Sickle Mice to Extracellular Heme Via Nrf2-Dependent Pathways. Blood, 2018, 132, 2392-2392.	0.6	0
61	Thrombospondinâ€1 gene polymorphism is associated with estimated pulmonary artery pressure in patients with sickle cell anemia. American Journal of Hematology, 2017, 92, E31-E34.	2.0	10
62	Prostacyclin-analog therapy in sickle cell pulmonary hypertension. Haematologica, 2017, 102, e163-e165.	1.7	15
63	Skeletal and myocardial microvascular blood flow in hydroxycarbamideâ€treated patients with sickle cell disease. British Journal of Haematology, 2017, 179, 648-656.	1.2	18
64	Lung vaso-occlusion in sickle cell disease mediated by arteriolar neutrophil-platelet microemboli. JCI Insight, 2017, 2, e89761.	2.3	95
65	The Defective Arginine-Nitric Oxide Pathway in Sickle Cell Disease. , 2017, , 355-371.		0
66	Intravascular hemolysis and the pathophysiology of sickle cell disease. Journal of Clinical Investigation, 2017, 127, 750-760.	3.9	435
67	Cellular biophysical markers of hydroxyurea treatment in sickle cell disease. , 2017, , .		0
68	Hairy Platelet-Derived Extracellular Vesicles Promote Lung Vaso-Occlusion in Sickle Cell Disease. Blood, 2017, 130, 958-958.	0.6	1
69	New insights into sickle cell disease. Current Opinion in Hematology, 2016, 23, 224-232.	1.2	30
70	Cellular normoxic biophysical markers of hydroxyurea treatment in sickle cell disease. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 9527-9532.	3.3	36
71	New developments in antiâ€sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin inÂvivo?. British Journal of Haematology, 2016, 175, 24-30.	1.2	58
72	Elevated transpulmonary gradient and cardiac magnetic resonance-derived right ventricular remodeling predict poor outcomes in sickle cell disease. Haematologica, 2016, 101, e40-e43.	1.7	10

#	Article	IF	Citations
73	Critical Reviews: How we treat sickle cell patients with leg ulcers. American Journal of Hematology, 2016, 91, 22-30.	2.0	56
74	Sickle Cell Imaging Flow Cytometry Assay (SIFCA). Methods in Molecular Biology, 2016, 1389, 279-292.	0.4	11
75	Inflammation and Sickle Cell Anemia. , 2016, , 177-211.		4
76	Neutrophil-Platelet Aggregation Enables Vaso-Occlusion in Sickle Cell Disease. Blood, 2016, 128, 1295-1295.	0.6	3
77	The Impact of Cognitive Function on Adherence to Hydroxyurea Therapy in Patients with Sickle Cell Disease. Blood, 2016, 128, 2493-2493.	0.6	3
78	Biophysical markers of Sickle Cell Disease at Individual Cell Level. , 2016, , .		0
79	Structural and Functional Insight of Sphingosine 1-Phosphate-Mediated Pathogenic Metabolic Reprogramming in Sickle Cell Disease. Blood, 2016, 128, 2474-2474.	0.6	0
80	Hospitalization for Acute Pain in Sickle Cell Disease: Changes in Clinical Parameters and Factors Predicting Hospital Discharge and Re-Admission. Blood, 2016, 128, 3662-3662.	0.6	0
81	Higher Myocardial and Skeletal Muscle Microvascular Flow in Sickle Cell Disease Patients on Hydroxyurea. Blood, 2016, 128, 1020-1020.	0.6	1
82	Amerindian/Asian Ancestry and Mortality Are Associated with Allo-Immunization in Adults with Sickle Cell Disease in a Genome Wide Racial Admixture Study. Blood, 2016, 128, 3650-3650.	0.6	0
83	Thrombospondin-1 Polymorphisms Are Associated with Chronic Kidney Disease in Sickle Cell Anemia. Blood, 2016, 128, 2491-2491.	0.6	0
84	Iron restriction in sickle cell anemia: Time for controlled clinical studies. American Journal of Hematology, 2015, 90, E217.	2.0	7
85	Liver injury is associated with mortality in sickle cell disease. Alimentary Pharmacology and Therapeutics, 2015, 42, 912-921.	1.9	44
86	Kinetics of sickle cell biorheology and implications for painful vasoocclusive crisis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 1422-1427.	3.3	99
87	Defective nitric oxide metabolism in sickle cell disease. Pediatric Blood and Cancer, 2015, 62, 373-374.	0.8	11
88	Management of Patients With Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2015, 313, 91.	3.8	4
89	Oscillatory haematopoiesis in adults with sickle cell disease treated with hydroxycarbamide. British Journal of Haematology, 2015, 168, 737-746.	1.2	6
90	Gout and sickle cell disease: not all pain is sickle cell pain. British Journal of Haematology, 2015, 171, 872-875.	1.2	6

#	Article	IF	Citations
91	Rapid vs. delayed infrared responses after ischemia reveal recruitment of different vascular beds. Quantitative InfraRed Thermography Journal, 2015, 12, 173-183.	2.1	7
92	Iron, Inflammation, and Early Death in Adults With Sickle Cell Disease. Circulation Research, 2015, 116, 298-306.	2.0	71
93	Association of FOXO3A Polymorphisms with Hematocrit, LDH and Longevity in Patients with Sickle Cell Anemia from CSSCD, Walk-Phasst, and PUSH Clinical Trials. Blood, 2015, 126, 2176-2176.	0.6	0
94	Thrombospondin-1 Gene Polymorphism Is Associated with Estimated Pulmonary Artery Pressure in Patients with Sickle Cell Anemia. Blood, 2015, 126, 970-970.	0.6	0
95	Platelet Nucleation on Arrested Neutrophils Drives Vaso-Occlusion in Sickle Cell Disease. Blood, 2015, 126, 414-414.	0.6	0
96	Heme Augments Toll-like Receptor 4 Signalling in Sickle Cell and Healthy Control Monocytes. Blood, 2015, 126, 2167-2167.	0.6	0
97	The Oxidant Response Transcription Factor NRF2 Mediates Heme Activation of Placenta Growth Factor Expression in Erythroid Cells, a Contributor to Pulmonary Hypertension in Sickle Cell Disease. Blood, 2015, 126, 403-403.	0.6	0
98	Elevated Pulse Pressure is Associated with Hemolysis, Proteinuria and Chronic Kidney Disease in Sickle Cell Disease. PLoS ONE, 2014, 9, e114309.	1.1	26
99	Reply: Practice Guideline for Pulmonary Hypertension in Sickle Cell: Direct Evidence Needed before Universal Adoption. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 238-240.	2.5	1
100	Sleep disturbance, depression and pain in adults with sickle cell disease. BMC Psychiatry, 2014, 14, 207.	1.1	78
101	A GCH1 haplotype confers sexâ€specific susceptibility to pain crises and altered endothelial function in adults with sickle cell anemia. American Journal of Hematology, 2014, 89, 187-193.	2.0	38
102	Abnormal Pulmonary Function and Associated Risk Factors in Children and Adolescents With Sickle Cell Anemia. Journal of Pediatric Hematology/Oncology, 2014, 36, 185-189.	0.3	44
103	A Retrospective Review of Acupuncture Use for the Treatment of Pain in Sickle Cell Disease Patients. Clinical Journal of Pain, 2014, 30, 825-830.	0.8	37
104	Computed Tomography Correlates with Cardiopulmonary Hemodynamics in Pulmonary Hypertension in Adults with Sickle Cell Disease. Pulmonary Circulation, 2014, 4, 319-329.	0.8	7
105	Therapeutic Strategies to Alter the Oxygen Affinity of Sickle Hemoglobin. Hematology/Oncology Clinics of North America, 2014, 28, 217-231.	0.9	65
106	Vasculopathy, inflammation, and blood flow in leg ulcers of patients with sickle cell anemia. American Journal of Hematology, 2014, 89, 1-6.	2.0	62
107	Imaging flow cytometry for automated detection of hypoxiaâ€induced erythrocyte shape change in sickle cell disease. American Journal of Hematology, 2014, 89, 598-603.	2.0	60
108	Topical sodium nitrite for chronic leg ulcers in patients with sickle cell anaemia: a phase 1 dose-finding safety and tolerability trial. Lancet Haematology,the, 2014, 1, e95-e103.	2.2	37

#	Article	IF	Citations
109	Microvascular oxygen consumption during sickle cell pain crisis. Blood, 2014, 123, 3101-3104.	0.6	13
110	Extensive Ex Vivo Expansion of Functional Human Erythroid Precursors Established From Umbilical Cord Blood Cells by Defined Factors. Molecular Therapy, 2014, 22, 451-463.	3.7	45
111	An Official American Thoracic Society Clinical Practice Guideline: Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell Disease. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 727-740.	2.5	197
112	Mo1001 Nodular Regenerative Hyperplasia: Many Ways to Get There. Gastroenterology, 2014, 146, S-983.	0.6	0
113	Prominent role of platelets in the formation of circulating neutrophil-red cell heterocellular aggregates in sickle cell anemia. Haematologica, 2014, 99, e214-e217.	1.7	34
114	Imaging flow cytometry documents incomplete resistance of human sickle F-cells to ex vivo hypoxia-induced sickling. Blood, 2014, 124, 658-660.	0.6	6
115	Heme-bound iron activates placenta growth factor in erythroid cells via erythroid KrÃ¼ppel-like factor. Blood, 2014, 124, 946-954.	0.6	40
116	No NO means yes to sickle red cell adhesion. Blood, 2014, 123, 1780-1782.	0.6	8
117	Elevated sphingosine-1-phosphate promotes sickling and sickle cell disease progression. Journal of Clinical Investigation, 2014, 124, 2750-2761.	3.9	112
118	Quantification of Anti-Sickling Effect of Aes-103 in Sickle Cell Disease Using an in Vitro Microfluidic Assay. Blood, 2014, 124, 2699-2699.	0.6	2
119	Stimulation of Nitric Oxide Synthase Activity By Plasma Apolipoproteins: a Biomarker of Endothelial Function in Adults with Sickle Cell Disease. Blood, 2014, 124, 4015-4015.	0.6	2
120	Risk Factors for Death in 632 Patients with Sickle Cell Disease in the United States and United Kingdom. PLoS ONE, 2014, 9, e99489.	1.1	107
121	Elevated sphingosine-1-phosphate promotes sickling and sickle cell disease progression. Journal of Clinical Investigation, 2014, 124, 3274-3274.	3.9	1
122	End-Alveolar Carbon Monoxide As a Measure of Erythrocyte Survival and Hemolytic Severity in Sickle Cell Disease. Blood, 2014, 124, 2696-2696.	0.6	0
123	Iron, Expression of the Pattern Recognition Receptor-Inflammasome System, and Early Death in Adults with Sickle Cell Disease. Blood, 2014, 124, 2702-2702.	0.6	1
124	Cardiopulmonary Functional Status in Children with SCD at Baseline: Pulse Pressure As a Biomarker of Early Compromise. Blood, 2014, 124, 2663-2663.	0.6	0
125	Elevated Pulse Pressure Is Associated with Hemolysis, Proteinuria and Chronic Kidney Disease in Sickle Cell Disease. Blood, 2014, 124, 2711-2711.	0.6	0
126	A fluorescence method to detect and quantitate sterol esterification by lecithin:cholesterol acyltransferase. Analytical Biochemistry, 2013, 441, 80-86.	1.1	16

#	Article	IF	Citations
127	RV dysfunction by MRI is associated with elevated transpulmonary gradient and poor prognosis in patients with sickle cell associated pulmonary hypertension. Journal of Cardiovascular Magnetic Resonance, 2013, 15, O43.	1.6	0
128	Leg Ulcers in Sickle Cell Disease: Current Patterns and Practices. Hemoglobin, 2013, 37, 325-332.	0.4	55
129	Effect of Extended-Release Niacin on Serum Lipids and on Endothelial Function in Adults With Sickle Cell Anemia and Low High-Density Lipoprotein Cholesterol Levels. American Journal of Cardiology, 2013, 112, 1499-1504.	0.7	10
130	Circulating Blood Endothelial Nitric Oxide Synthase Contributes to the Regulation of Systemic Blood Pressure and Nitrite Homeostasis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1861-1871.	1.1	105
131	Genetic determinants of haemolysis in sickle cell anaemia. British Journal of Haematology, 2013, 161, 270-278.	1.2	45
132	Imaging flow cytometry for morphologic and phenotypic characterization of rare circulating endothelial cells. Cytometry Part B - Clinical Cytometry, 2013, 84, 379-389.	0.7	33
133	Mechanisms of hemolysisâ€associated platelet activation. Journal of Thrombosis and Haemostasis, 2013, 11, 2148-2154.	1.9	144
134	Thrombospondin-1 inhibits ADAMTS13 activity in sickle cell disease. Haematologica, 2013, 98, e132-e134.	1.7	35
135	Hemodynamic Predictors of Mortality in Adults with Sickle Cell Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 840-847.	2.5	114
136	The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica, 2013, 98, 464-472.	1.7	170
137	Reduced sensitivity of the ferroportin Q248H mutant to physiological concentrations of hepcidin. Haematologica, 2013, 98, 455-463.	1.7	26
138	Circulating Endothelial Progenitor Cells in Adults with Sickle Cell Disease. Pulmonary Circulation, 2013, 3, 448-449.	0.8	2
139	Clinical correlates of acute pulmonary events in children and adolescents with sickle cell disease. European Journal of Haematology, 2013, 91, 62-68.	1.1	30
140	Liver stiffness increases acutely during sickle cell vasoâ€occlusive crisis. American Journal of Hematology, 2013, 88, E250-4.	2.0	14
141	Lactate dehydrogenase and hemolysis in sickle cell disease. Blood, 2013, 122, 1091-1092.	0.6	19
142	Expression of Regulatory Platelet MicroRNAs in Patients with Sickle Cell Disease. PLoS ONE, 2013, 8, e60932.	1.1	21
143	Phase 1 Clinical Trial Of The Candidate Anti-Sickling Agent Aes-103 In Adults With Sickle Cell Anemia. Blood, 2013, 122, 1009-1009.	0.6	18
144	The Anti-Sickling Agent Aes-103 Decreases Sickle Erythrocyte Fragility, Hypoxia-Induced Sickling and Hemolysis In Vitro. Blood, 2013, 122, 940-940.	0.6	4

#	Article	IF	Citations
145	Severe Painful Vaso-Occlusive Crises and Mortality in a Contemporary Adult Sickle Cell Anemia Cohort Study. PLoS ONE, 2013, 8, e79923.	1.1	91
146	Topical Sodium Nitrite Is Effective In Reducing Leg Ulcer-Associated Pain In Patients With Sickle Cell Disease. Blood, 2013, 122, 2236-2236.	0.6	0
147	Imaging Flow Cytometry and Microfluidic Flow Assays Demonstrate Heterocellular Aggregation Of Immature Sickle Erythrocytes To Neutrophils Via Mac-1/VLA-4 Interactions. Blood, 2013, 122, 318-318.	0.6	1
148	Placenta Growth Factor Is Regulated By Heme-Bound Iron Via Erythroid KrÃ¼ppel-Like Factor In Erythroid Cells and Is Linked To Iron Status In Vivo In Sickle Cell Disease and Hereditary Hemochromatosis. Blood, 2013, 122, 432-432.	0.6	0
149	Imaging Flow Cytometry Documents Incomplete Resistance Of F-Cells To Hypoxia-Induced Sickling In Blood Samples From Patients With Sickle Cell Anemia. Blood, 2013, 122, 183-183.	0.6	0
150	A Novel Molecular Signature for Elevated Tricuspid Regurgitation Velocity in Sickle Cell Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 359-368.	2.5	39
151	Pulmonary Complications of Sickle Cell Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 1154-1165.	2.5	143
152	Reconstruction of thermographic signals to map perforator vessels in humans. Quantitative InfraRed Thermography Journal, 2012, 9, 123-133.	2.1	14
153	Characterizing non-linear dependencies among pairs of clinical variables and imaging data. , 2012, 2012, 2700-3.		3
154	Mortality in Adults With Sickle Cell Disease and Pulmonary Hypertension. JAMA - Journal of the American Medical Association, 2012, 307, 1254.	3.8	179
155	Atorvastatin reduces serum cholesterol and triglycerides with limited improvement in vascular function in adults with sickle cell anemia. Haematologica, 2012, 97, 1768-1770.	1.7	17
156	An Elevated Tricuspid Regurgitant Jet Velocity In Sickle Cell Disease Is Associated With Polymorphisms In Genes Impacting Innate Immunity. , 2012, , .		0
157	Computer-assisted diagnostic tool to quantify the pulmonary veins in sickle cell associated pulmonary hypertension. Proceedings of SPIE, 2012, , .	0.8	0
158	Pulmonary artery pressure and iron deficiency in patients with upregulation of hypoxia sensing due to homozygous VHLR200W mutation (Chuvash polycythemia). Haematologica, 2012, 97, 193-200.	1.7	26
159	Infusion of hemolyzed red blood cells within peripheral blood stem cell grafts in patients with and without sickle cell disease. Blood, 2012, 119, 5671-5673.	0.6	5
160	Meta-analysis of 2040 sickle cell anemia patients: BCL11A and HBS1L-MYB are the major modifiers of HbF in African Americans. Blood, 2012, 120, 1961-1962.	0.6	73
161	Non-invasive indicators of pulmonary hypertension from pulmonary veins quantification in sickle cell disease. , 2012, , .		1
162	Anemia, age, desaturation, and impaired neurocognition in sickle cell anemia. Pediatric Blood and Cancer, 2012, 59, 773-774.	0.8	2

#	Article	IF	Citations
163	A systematic comparison and evaluation of high density exon arrays and RNA-seq technology used to unravel the peripheral blood transcriptome of sickle cell disease. BMC Medical Genomics, 2012, 5, 28.	0.7	71
164	Dietâ€Induced Weight Loss in Overweight or Obese Women and Changes in Highâ€Density Lipoprotein Levels and Function. Obesity, 2012, 20, 2057-2062.	1.5	45
165	Infrared imaging of nitric oxide-mediated blood flow in human sickle cell disease. Microvascular Research, 2012, 84, 262-269.	1.1	17
166	Understanding the Erythrocyte Storage Lesion. Anesthesiology, 2012, 117, 1159-1161.	1.3	3
167	TRV: A physiological biomarker in sickle cell disease. Pediatric Blood and Cancer, 2012, 58, 831-832.	0.8	14
168	High-Density Lipoprotein Cholesterol Efflux, Nitration of Apolipoprotein A-I, and Endothelial Function in Obese Women. American Journal of Cardiology, 2012, 109, 527-532.	0.7	19
169	Priapism in Sickle-Cell Disease: A Hematologistâ€™s Perspective. Journal of Sexual Medicine, 2012, 9, 70-78.	0.3	33
170	Markers of Severe Vaso-Occlusive Painful Episode Frequency in Children and Adolescents with Sickle Cell Anemia. Journal of Pediatrics, 2012, 160, 286-290.	0.9	84
171	Framing the research agenda for sickle cell trait: Building on the current understanding of clinical events and their potential implications. American Journal of Hematology, 2012, 87, 340-346.	2.0	72
172	Plasma thrombospondinâ€1 is increased during acute sickle cell vasoâ€occlusive events and associated with acute chest syndrome, hydroxyurea therapy, and lower hemolytic rates. American Journal of Hematology, 2012, 87, 326-330.	2.0	68
173	Imaging Flow Cytometry for Fully Automated Quantification of Percentage of Sickled Cells in Sickle Cell Anemia.. Blood, 2012, 120, 2105-2105.	0.6	1
174	A Phase 1, First-in-Man, Dose-Response Study of Aes-103 (5-HMF), an Anti-Sickling, Allosteric Modifier of Hemoglobin Oxygen Affinity in Healthy Norman Volunteers. Blood, 2012, 120, 3210-3210.	0.6	19
175	Effect of Aes-103 Anti-Sickling Agent On Oxygen Affinity and Stability of Red Blood Cells From Patients with Sickle Cell Anemia. Blood, 2012, 120, 85-85.	0.6	1
176	Comment on "The influence of hydroxyurea on oxidative stress in sickle cell anemia". Revista Brasileira De Hematologia E Hemoterapia, 2012, 34, 405-406.	0.7	3
177	Increased Transpulmonary Gradient Predicts Functional Class, Mortality, and RV Dysfunction by MRI in Patients with Sickle Cell Associated Pulmonary Hypertension. Blood, 2012, 120, 89-89.	0.6	0
178	Turnover of Heme-Bound Iron Is Associated with Activation of TLR4 and Chemokine Receptor Pathways in the Peripheral Blood Mononuclear Cell Transcriptome in Sickle Cell Anemia. Blood, 2012, 120, 819-819.	0.6	0
179	Laser Speckle Contrast Imaging Characterizes Delayed Reperfusion After Transient Brachial Artery Occlusion in Patients with Sickle Cell Diseas. Blood, 2012, 120, 1080-1080.	0.6	0
180	A Phase 1, Dose-Escalation Study of Topical Sodium Nitrite in Patients with Sickle Cell Anemia and Leg Ulcers. Blood, 2012, 120, 86-86.	0.6	1

#	Article	IF	Citations
181	Genetic Determinants of Hemolysis in Sickle Cell Anemia.. Blood, 2012, 120, 2104-2104.	0.6	0
182	Blood Flow Is Increased in Wounds and Peri-Wound Area by Laser Speckle Contrast Imaging and Infrared Thermography in Adults with Sickle Cell Leg Ulcers. Blood, 2012, 120, 1009-1009.	0.6	1
183	Ancestry of African Americans with sickle cell disease. Blood Cells, Molecules, and Diseases, 2011, 47, 41-45.	0.6	35
184	Study Of Clinical Characteristics Of Sickle Cell Disease Patients Developing Cor-Pulmonale During Acute Hospitalization. , 2011, , .		0
185	Pulmonary Function In Adults With Sickle Cell Related Pulmonary Hypertension. , 2011, , .		0
186	Abnormal Methacholine Challenge Associated With Pulmonary Arterial Hypertension In Adults With Sickle Cell Disease. , 2011, , .		0
187	Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood, 2011, 118, 855-864.	0.6	210
188	Elevated tricuspid regurgitation velocity and decline in exercise capacity over 22 months of follow up in children and adolescents with sickle cell anemia. Haematologica, 2011, 96, 33-40.	1.7	71
189	Predictors of osteoclast activity in patients with sickle cell disease. Haematologica, 2011, 96, 1092-1098.	1.7	18
190	Antiâ€haemolytic effect of senicapoc and decrease in NTâ€proBNP in adults with sickle cell anaemia. British Journal of Haematology, 2011, 155, 634-636.	1.2	6
191	NTâ€pro brain natriuretic peptide levels and the risk of death in the cooperative study of sickle cell disease. British Journal of Haematology, 2011, 154, 512-520.	1.2	51
192	Laboratory and echocardiography markers in sickle cell patients with leg ulcers. American Journal of Hematology, 2011, 86, 705-708.	2.0	42
193	Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis. JAMA - Journal of the American Medical Association, 2011, 305, 893.	3.8	196
194	Echocardiographic Markers of Elevated Pulmonary Pressure and Left Ventricular Diastolic Dysfunction Are Associated With Exercise Intolerance in Adults and Adolescents With Homozygous Sickle Cell Anemia in the United States and United Kingdom. Circulation, 2011, 124, 1452-1460.	1.6	124
195	Clinical and Genetic Variability of Red Blood Cell Hemolysis in Sickle Cell Anemia. Blood, 2011, 118, 1077-1077.	0.6	6
196	Health Care Utilization for Painful Events Is Associated with Early Mortality in a Contemporary Population of Adults with Sickle Cell Anemia. Blood, 2011, 118, 2115-2115.	0.6	1
197	Predictors of Mortality in Children and Adolescents with Sickle Cell Disease: The PUSH Study. Blood, 2011, 118, 515-515.	0.6	1
198	Serum Transferrin: An Independent Predictor of Mortality in Sickle Cell Anemia. Blood, 2011, 118, 2126-2126.	0.6	0

#	Article	IF	Citations
199	A Cell-Based Adhesion Molecule Bioassay Detects Unexpected Properties of Plasma From Patients with Sickle Cell Disease with Documented Pulmonary Hypertension. Blood, 2011, 118, 2120-2120.	0.6	0
200	Iron Containing Compound Stimulates Expression of Pulmonary Hypertension Promoting Factor PlGF. Blood, 2011, 118, 900-900.	0.6	0
201	Integration of Genomic and Genetic Approaches Highlight a Novel Validated Gene Signature for Pulmonary Hypertension Associated with Sickle Cell Disease. Blood, 2011, 118, 511-511.	0.6	0
202	Non-Cardiopulmonary Factors Affecting the Six-Minute Walk Distance in Patients with Sickle Cell Disease: Results From the Walk-PHaSST Study. Blood, 2011, 118, 1074-1074.	0.6	1
203	Segmentation and quantification of pulmonary artery for noninvasive CT assessment of sickle cell secondary pulmonary hypertension. Medical Physics, 2010, 37, 1522-1532.	1.6	30
204	Diastolic dysfunction in sickle cell. Blood, 2010, 116, 1-2.	0.6	48
205	Pulmonary hypertension and NO in sickle cell. Blood, 2010, 116, 852-854.	0.6	59
206	High levels of placenta growth factor in sickle cell disease promote pulmonary hypertension. Blood, 2010, 116, 109-112.	0.6	77
207	Apolipoprotein A-I and serum amyloid A plasma levels are biomarkers of acute painful episodes in patients with sickle cell disease. Haematologica, 2010, 95, 1467-1472.	1.7	19
208	Pleiotropic effects of intravascular haemolysis on vascular homeostasis. British Journal of Haematology, 2010, 148, 690-701.	1.2	62
209	Lipid levels in sickleâ€cell disease associated with haemolytic severity, vascular dysfunction and pulmonary hypertension. British Journal of Haematology, 2010, 149, 436-445.	1.2	70
210	NTâ€proBNP as a marker of cardiopulmonary status in sickle cell anaemia in Africa. British Journal of Haematology, 2010, 150, 102-107.	1.2	9
211	Association of G6PD^{202A,376G} with lower haemoglobin concentration but not increased haemolysis in patients with sickle cell anaemia. British Journal of Haematology, 2010, 150, 218-225.	1.2	31
212	Longitudinal Change In Pulmonary Function In Children With Sickle Cell Disease And Associated Factors. , 2010, , .		0
213	Increased Pulmonary Pressures and Myocardial Wall Stress in Children with Severe Malaria. Journal of Infectious Diseases, 2010, 202, 791-800.	1.9	44
214	The proteome of sickle cell disease: insights from exploratory proteomic profiling. Expert Review of Proteomics, 2010, 7, 833-848.	1.3	20
215	Evaluation Of Sildenafil Therapy For Patients With Sickle Cell Disease And Increased Tricuspid Regurgitant Velocity: Preliminary Results Of The Walk-PHaSST Trial. , 2010, , .		3
216	Hydroxyurea-Induced Expression of Glutathione Peroxidase 1 in Red Blood Cells of Individuals with Sickle Cell Anemia. Antioxidants and Redox Signaling, 2010, 13, 1-11.	2.5	47

#	Article	IF	Citations
217	Effects of a Single Sickling Event on the Mechanical Fragility of Sickle Cell Trait Erythrocytes. Hemoglobin, 2010, 34, 24-36.	0.4	14
218	Risk Factors for Echocardiography-Determined Cardiopulmonary Abnormalities In Sickle Cell Anemia In the Walk-PHaSST Study. Blood, 2010, 116, 260-260.	0.6	3
219	Hemodynamic Parameters Predict Mortality In Sickle Cell Disease-Related Pulmonary Hypertension. Blood, 2010, 116, 2668-2668.	0.6	3
220	Plasma Level of NT-Pro-BNP In Children with Sickle Cell Disease Is Associated with Degree of Anemia and Left Ventricular Measures: The PUSH Study. Blood, 2010, 116, 948-948.	0.6	2
221	Plasma Thrombospondin 1 Is Increased and Associated with Markers of Vasculopathy In Sickle Cell Disease. Blood, 2010, 116, 946-946.	0.6	0
222	NT-Probnp as a Marker of Cardiopulmonary Compromise and Exercise Limitation In Adults with Sickle Cell Anemia In the Walk-PHaSST Study. Blood, 2010, 116, 1639-1639.	0.6	0
223	Predictors of Six-Minute Walk Distance In Adults with Sickle Cell Anemia In the Walk-PHaSST Study. Blood, 2010, 116, 947-947.	0.6	1
224	Chronic Pain Is An Independent Predictor of Lower 6 Minute Walk Distance In Patients with Sickle Cell Disease: Results From Walk-PHaSST Study. Blood, 2010, 116, 2658-2658.	0.6	0
225	Evaluation of Exercise Capacity In Children with SCD by Six Minute Walk Test. Blood, 2010, 116, 2664-2664.	0.6	0
226	Serum B12 Levels In Children with Sickle Cell Disease Are Lower Than In Healthy Control Subjects. Blood, 2010, 116, 1647-1647.	0.6	0
227	Mechanisms and Clinical Complications of Hemolysis in Sickle Cell Disease and Thalassemia. , 2009, , 201-224.		9
228	Angiogenic and Inflammatory Markers of Cardiopulmonary Changes in Children and Adolescents with Sickle Cell Disease. PLoS ONE, 2009, 4, e7956.	1.1	61
229	Near-infrared spectra absorbance of blood from sickle cell patients and normal individuals. Hematology, 2009, 14, 46-48.	0.7	27
230	Pulmonary Complications of Sickle Cell Disease. New England Journal of Medicine, 2009, 360, 1044-1045.	13.9	3
231	Strategic Plan for Pediatric Respiratory Diseases Research: An NHLBI Working Group Report. Proceedings of the American Thoracic Society, 2009, 6, 1-10.	3.5	18
232	Hematologic, biochemical, and cardiopulmonary effects of <scp>l</scp>â€arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy. European Journal of Haematology, 2009, 82, 315-321.	1.1	58
233	Prospective Echocardiography Assessment of Pulmonary Hypertension and Its Potential Etiologies in Children With Sickle Cell Diseaseâ€â€Conflicts of interest: Dr. Gordeuk has received grants from BioMarin Pharmaceutical Inc., Novato, California, and Actelion Pharmaceuticals Ltd., Allschwil, Switzerland, and is a consultant for Ikaria Holdings, Clinton, New Jersey.. American Journal of Cardiology, 2009, 104, 713-720.	0.7	56
234	Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea. American Journal of Hematology, 2009, 84, 529-531.	2.0	37

#	Article	IF	Citations
235	Strategic plan for pediatric respiratory diseases research: An NHLBI working group report. Pediatric Pulmonology, 2009, 44, 2-13.	1.0	12
236	Endogenous nitric oxide synthase inhibitors in sickle cell disease: abnormal levels and correlations with pulmonary hypertension, desaturation, haemolysis, organ dysfunction and death. British Journal of Haematology, 2009, 145, 506-513.	1.2	85
237	Prospective evaluation of haemoglobin oxygen saturation at rest and after exercise in paediatric sickle cell disease patients. British Journal of Haematology, 2009, 147, 352-359.	1.2	59
238	Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease. British Journal of Haematology, 2009, 147, 737-743.	1.2	69
239	Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation. Haematologica, 2009, 94, 340-347.	1.7	164
240	Proteomic identification of altered apolipoprotein patterns in pulmonary hypertension and vasculopathy of sickle cell disease. Blood, 2009, 113, 1122-1128.	0.6	70
241	Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease. Blood, 2009, 114, 4639-4644.	0.6	62
242	Vascular complications after splenectomy for hematologic disorders. Blood, 2009, 114, 5404-5404.	0.6	10
243	Haptoglobin halts hemoglobinâ€™s havoc. Journal of Clinical Investigation, 2009, 119, 2140-2.	3.9	44
244	NT-Pro Brain Natriuretic Peptide Levels and the Risk of Stroke and Death in the Cooperative Study of Sickle Cell Disease.. Blood, 2009, 114, 1541-1541.	0.6	6
245	Genetic Polymorphisms in NEDD4L Are Associated with Pulmonary Hypertension of Sickle Cell Anemia.. Blood, 2009, 114, 2562-2562.	0.6	1
246	Thrombin Generation in Sickle Cell Disease: Insights From Computerized Automated Thrombography.. Blood, 2009, 114, 2587-2587.	0.6	6
247	Safety and Efficacy of Sildenafil Therapy for Doppler-Defined Pulmonary Hypertension in Patients with Sickle Cell Disease: Preliminary Results of the Walk-PHaSST Clinical Trial.. Blood, 2009, 114, 571-571.	0.6	13
248	A GCH1 Haplotype Associated with Susceptibility to Vasoocclusive Pain and Impaired Vascular Function in Sickle Cell Anemia.. Blood, 2009, 114, 575-575.	0.6	5
249	Cytochrome b5 Reductase T116S Mutation and Hemolysis in Sickle Cell Disease.. Blood, 2009, 114, 903-903.	0.6	1
250	Iron deficiency decreases hemolysis in sickle cell anemia. Revista Brasileira De Hematologia E Hemoterapia, 2009, 31, 51-53.	0.7	6
251	Placental Growth Factor Is Elevated in Patients with Sickle Cell Disease and Associated with Pulmonary Hypertension, Hemolysis, Inflammation, Iron Overload, and Hepatic Dysfunction.. Blood, 2009, 114, 1531-1531.	0.6	0
252	Lower Ferritin Concentrations Are Associated with Decreased Hemolysis in Sickle Cell Disease Children without Iron Overload.. Blood, 2009, 114, 2571-2571.	0.6	0

#	Article	IF	Citations
253	Hemolysis-Associated Elevation in Tricuspid Regurgitation Velocity Predicts Reduction in Six-Minute Walk Distance After Two Years of Follow up in Children and Adolescents with Sickle Cell Disease.. Blood, 2009, 114, 574-574.	0.6	0
254	Association of G6PD â˜’202/â˜’376 with Lower Hemoglobin Concentration but Not Increased Hemolysis in Patients with Sickle Cell Anemia.. Blood, 2009, 114, 1511-1511.	0.6	0
255	Sickle Cell Leg Ulcers Are Associated with Hyperuricemia, Hemolysis, Pulmonary Hypertension and Death.. Blood, 2009, 114, 2583-2583.	0.6	1
256	Pulmonary Hypertension in Children and Adolescents with Sickle Cell Disease. Pediatric Cardiology, 2008, 29, 309-312.	0.6	89
257	Corticosteroids and increased risk of readmission after acute chest syndrome in children with sickle cell disease. Pediatric Blood and Cancer, 2008, 50, 1006-1012.	0.8	97
258	Relative systemic hypertension in patients with sickle cell disease is associated with risk of pulmonary hypertension and renal insufficiency. American Journal of Hematology, 2008, 83, 15-18.	2.0	108
259	Mutations and polymorphisms in hemoglobin genes and the risk of pulmonary hypertension and death in sickle cell disease. American Journal of Hematology, 2008, 83, 6-14.	2.0	60
260	Severe pulmonary hypertension in an adolescent with sickle cell disease. American Journal of Hematology, 2008, 83, 71-72.	2.0	5
261	Sickle cell disease and pulmonary hypertension in Africa: A global perspective and review of epidemiology, pathophysiology, and management. American Journal of Hematology, 2008, 83, 63-70.	2.0	91
262	Prevalence and risk factors for pulmonary artery systolic hypertension among sickle cell disease patients in Nigeria. American Journal of Hematology, 2008, 83, 485-490.	2.0	93
263	Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemia. British Journal of Haematology, 2008, 141, 254-259.	1.2	49
264	Sodium nitrite promotes regional blood flow in patients with sickle cell disease: a phase I/II study. British Journal of Haematology, 2008, 142, 971-978.	1.2	59
265	Evolution of Novel Small-Molecule Therapeutics Targeting Sickle Cell Vasculopathy. JAMA - Journal of the American Medical Association, 2008, 300, 2638.	3.8	74
266	Hemolysis-associated hypercoagulability in sickle cell disease: the plot (and blood) thickens!. Haematologica, 2008, 93, 1-3.	1.7	61
267	Nitric Oxide and Arginine Dysregulation: A Novel Pathway to Pulmonary Hypertension in Hemolytic Disorders. Current Molecular Medicine, 2008, 8, 620-632.	0.6	95
268	Novel Small Molecule Therapeutics for Sickle Cell Disease: Nitric Oxide, Carbon Monoxide, Nitrite, and Apolipoprotein A-I. Hematology American Society of Hematology Education Program, 2008, 2008, 186-192.	0.9	22
269	Chronic Hyper-Hemolysis in Sickle Cell Anemia: Association of Vascular Complications and Mortality with Less Frequent Vasoocclusive Pain. PLoS ONE, 2008, 3, e2095.	1.1	152
270	Association of Hemolysis with Clinical Manifestations of Sickle Cell Disease. Blood, 2008, 112, 2482-2482.	0.6	0

#	Article	IF	Citations
271	Lower Ferritin Concentrations in Children with Sickle Cell Disease Are Associated with Decreased Hemolysis and Lower Tricuspid Regurgitant Velocity. Blood, 2008, 112, 4810-4810.	0.6	0
272	Oxygen Desaturation at Rest and after Exercise in Pediatric Sickle Cell Disease Patients: Correlations with Hemolysis and Elevated Tricuspid Regurgitant Jet Velocity.. Blood, 2008, 112, 1423-1423.	0.6	0
273	PULMONARY HYPERTENSION IN SICKLE CELL DISEASE: Relevance to Children. Pediatric Hematology and Oncology, 2007, 24, 159-170.	0.3	93
274	Amplified Expression Profiling of Platelet Transcriptome Reveals Changes in Arginine Metabolic Pathways in Patients With Sickle Cell Disease. Circulation, 2007, 115, 1551-1562.	1.6	126
275	Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood, 2007, 110, 2166-2172.	0.6	316
276	A network model to predict the risk of death in sickle cell disease. Blood, 2007, 110, 2727-2735.	0.6	159
277	Diastolic Dysfunction Is an Independent Risk Factor for Death in Patients With Sickle Cell Disease. Journal of the American College of Cardiology, 2007, 49, 472-479.	1.2	265
278	Deconstructing sickle cell disease: Reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Reviews, 2007, 21, 37-47.	2.8	728
279	Severity of pulmonary hypertension during vaso-occlusive pain crisis and exercise in patients with sickle cell disease. British Journal of Haematology, 2007, 136, 319-325.	1.2	109
280	Hydroxyurea Utilization in Nigeria, a Lesson in Public Health.. Blood, 2007, 110, 80-80.	0.6	19
281	Detection of the mRNA Transcription Level of Several Genes of the HIF and NO Metabolic Pathways in PBMCs of Sickle Cell Disease Patients Using Quantitative RT-PCR Assay.. Blood, 2007, 110, 844-844.	0.6	0
282	Phosphodiesterase Inhibition Increases Fetal Hemoglobin in Sickle Cell Disease; L-Arginine Supplementation Does Not.. Blood, 2007, 110, 3396-3396.	0.6	0
283	Prospective Evaluation of the Prevalence of Elevated Tricuspid Regurgitant Jet Velocity and Associated Clinical and Echocardiographic Factors in Children and Adolescents with Sickle Cell Disease.. Blood, 2007, 110, 3388-3388.	0.6	2
284	Sickle cell disease and nitric oxide: A paradigm shift?. International Journal of Biochemistry and Cell Biology, 2006, 38, 1237-1243.	1.2	121
285	A novel defense against hemolytic-oxidative stress. Blood, 2006, 108, 2504-2505.	0.6	2
286	Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood, 2006, 107, 2279-2285.	0.6	561
287	N-Terminal Pro-Brain Natriuretic Peptide Levels and Risk of Death in Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2006, 296, 310.	3.8	169
288	Cerebrovascular disease associated with sickle cell pulmonary hypertension. American Journal of Hematology, 2006, 81, 503-510.	2.0	90

#	Article	IF	Citations
289	Oral Arginine Increases Erythrocyte Glutathione Levels in Sickle Cell Disease: Implications for Pulmonary Hypertension.. Blood, 2006, 108, 1208-1208.	0.6	7
290	The Hyperhemolysis Phenotype in Sickle Cell Anemia: Increased Risk of Leg Ulcers, Priapism, Pulmonary Hypertension and Death with Decreased Risk of Vasoocclusive Events.. Blood, 2006, 108, 787-787.	0.6	4
291	Mutations and Polymorphisms Influencing Hemolysis in Hemoglobin Genes and Risk of Pulmonary Hypertension in Sickle Cell Disease: Effect of Hemoglobin SC.. Blood, 2006, 108, 1206-1206.	0.6	0
292	Arginine Metabolite Profiling in Sickle Cell Disease: Abnormal Levels and Correlations with Pulmonary Hypertension, Desaturation, Hemolysis and Organ Dysfunction.. Blood, 2006, 108, 1205-1205.	0.6	0
293	Amplified Expression Profiling of Platelet Transcriptome Reveals Global Activation of Arginine Metabolic Pathways in Patients with Sickle Cell Disease.. Blood, 2006, 108, 1536-1536.	0.6	0
294	Current therapy of sickle cell disease. Haematologica, 2006, 91, 7-10.	1.7	102
295	Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. Haematologica, 2006, 91, 1076-83.	1.7	45
296	Hemolysis-Associated Pulmonary Hypertension in Thalassemia. Annals of the New York Academy of Sciences, 2005, 1054, 481-485.	1.8	96
297	Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. British Journal of Haematology, 2005, 130, 445-453.	1.2	192
298	Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality. British Journal of Haematology, 2005, 130, 943-953.	1.2	188
299	Dysregulated Arginine Metabolism, Hemolysis-Associated Pulmonary Hypertension, and Mortality in Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2005, 294, 81.	3.8	619
300	Arginine Metabolism, Pulmonary Hypertension, and Sickle Cell Diseaseâ€"Reply. JAMA - Journal of the American Medical Association, 2005, 294, 2432.	3.8	1
301	Cardiopulmonary Complications of Sickle Cell Disease: Role of Nitric Oxide and Hemolytic Anemia. Hematology American Society of Hematology Education Program, 2005, 2005, 51-57.	0.9	93
302	Diastolic Dysfunction Is an Independent Risk Factor for Death in Patients with Sickle Cell Disease.. Blood, 2005, 106, 206-206.	0.6	4
303	Proteomic Identification of Dysregulated Apolipoprotein Expression in Pulmonary Hypertension Secondary to Sickle Cell Disease.. Blood, 2005, 106, 3168-3168.	0.6	0
304	Platelet Activation Is Linked to the Severity of Pulmonary Hypertension in Sickle Cell Disease and Normalizes on Sildenafil Therapy.. Blood, 2005, 106, 3166-3166.	0.6	3
305	Pulmonary Hypertension in Sickle Cell Disease: Cardiopulmonary Evaluation and Response to Chronic Phosphodiesterase 5 Inhibitor Therapy.. Blood, 2004, 104, 235-235.	0.6	13
306	Identification and characterization of the novel centrosome-associated protein CCCAP. Gene, 2003, 303, 35-46.	1.0	27

#	Article	IF	Citations
307	Tumor Pseudosyncytiae. New England Journal of Medicine, 2003, 348, 1348-1348.	13.9	1
308	Inhibition of PDE4 phosphodiesterase activity induces growth suppression, apoptosis, glucocorticoid sensitivity, p53, and p21WAF1/CIP1 proteins in human acute lymphoblastic leukemia cells. Blood, 2002, 99, 3390-3397.	0.6	79
309	Human genetic diseases of proteolysis. Human Mutation, 1999, 13, 87-98.	1.1	36
310	Homozygous factorâ€V mutation as a genetic cause of perinatal thrombosis and cerebral palsy. Developmental Medicine and Child Neurology, 1999, 41, 777-780.	1.1	2
311	Homozygous factor-V mutation as a genetic cause of perinatal thrombosis and cerebral palsy. Developmental Medicine and Child Neurology, 1999, 41, 777-780.	1.1	30
312	Successful Treatment of Life-Threatening Acute Chest Syndrome of Sickle Cell Disease with Venovenous Extracorporeal Membrane Oxygenation. Journal of Pediatric Hematology/Oncology, 1997, 19, 459-461.	0.3	29
313	The mUBC9 murine ubiquitin conjugating enzyme interacts with the E2A transcription factors. Gene, 1997, 201, 169-177.	1.0	18
314	E2A Basic-Helix-Loop-Helix Transcription Factors are Negatively Regulated by Serum Growth Factors and by the Id3 Protein. Nucleic Acids Research, 1996, 24, 2813-2820.	6.5	60
315	High glucocorticoid receptor content of leukemic blasts is a favorable prognostic factor in childhood acute lymphoblastic leukemia. Blood, 1993, 82, 2304-2309.	0.6	36
316	DNA binding by the Myc oncoproteins. Cancer Treatment and Research, 1993, 63, 313-325.	0.2	10
317	Max: functional domains and interaction with c-Myc.. Genes and Development, 1992, 6, 81-92.	2.7	266
318	Review of Five therapists and one client.. Psychotherapy, 1992, 29, 686-687.	0.7	0
319	Activation domains of L-Myc and c-Myc determine their transforming potencies in rat embryo cells.. Molecular and Cellular Biology, 1992, 12, 3130-3137.	1.1	77
320	Discrimination between related DNA sites by a single amino acid residue of Myc-related basic-helix-loop-helix proteins.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 599-602.	3.3	179
321	Function of the câ€Myc oncoprotein. FASEB Journal, 1992, 6, 3065-3072.	0.2	155
322	Intracellular leucine zipper interactions suggest c-Myc hetero-oligomerization.. Molecular and Cellular Biology, 1991, 11, 954-962.	1.1	166
323	Low-dose methotrexate therapy for hepatoblastoma. Cancer Chemotherapy and Pharmacology, 1991, 28, 233-234.	1.1	2
324	An amino-terminal c-myc domain required for neoplastic transformation activates transcription.. Molecular and Cellular Biology, 1990, 10, 5914-5920.	1.1	410

#	Article	IF	Citations
325	Childhood Hodgkin and Non-Hodgkin Lymphomas. Pediatrics in Review, 1990, 12, 171-179.	0.2	5
326	Sickle Cell Disease-Associated Pulmonary Hypertension: The Effect of Anemia and High Cardiac Output. International Journal of Clinical Reviews, 0, , .	0.1	0